MedX Health Corp Reports Year End 2008 Financial Results

    49% Gain In Last Half of 2008 Compared To Last Half of 2007

    MISSISSAUGA, ON, April 30 /CNW/ - MedX Health Corp., (TSXV.MDX) a global
leader in drug free, non-invasive low level laser and light therapy for tissue
repair and pain relief, today announced its results for the year ended
December 31, 2008
    Revenue for the year ended December 31, 2008 was $1,149,478, an 8.9 per
cent increase over 2007 year end revenue of $1,055,792. This revenue also
represents a 49% gain in the last six months of 2008 versus the last six
months of 2007. MedX incurred a loss from continuing operations for the year
of $2,759,627 or $0.11 per share compared to a loss of $2,091,170 or $0.14 per
share for the same period in the prior year.
    "For the first time in many years, MedX continues to post strong
increases versus the previous period in 2007," said Steven Guillen, chief
executive officer and president of MedX Health. "This is a direct result of
two new strategic partnerships with Technology4Medicine and Richmar/Naimco,
which are beginning to generate revenue. We are pleased with the revenue
growth over the last six months of 49% versus the previous year, especially in
light of the difficult market conditions. We expect to continue this trend of
revenue growth in 2009."

    Recent Company Highlights:

    -   Received CE mark for all products, which allows MedX to begin selling
        in 27 countries associated with the European Community (MedX Health
        Receives CE Mark for Laser and Light Products, March 4, 2009).

    -   Launched IRB (Investigational Review Board) approved program for
        treating addictions; smoking, alcohol, and drug abuse. This
        incorporates the MedX acupuncture laser with expert training with the
        goal of expanding the scope of an individual practice to a full
        franchise opportunity (MedX Health Announces Initiation of Laser
        Acupuncture Study for Controlling Addiction, January 22, 2009).

    -   Achieved ISO re-certification, demonstrating to outside regulatory
        bodies that the highest quality standards are in place (MedX Health
        Receives CE Mark for Laser and Light Products, March 4, 2009).

    -   Announced a newly allowed wound healing patent covering a laser and
        light therapy apparatus and method for bone healing, bone growth
        stimulation, and bone cartilage regeneration (MedX Health Announces
        Patent Allowance for Use of Laser and Light Probe for Bone Healing,
        February 23, 2009)

    Canadian $                                       2008           2007
    Revenue                                       1,149,478      1,055,792
    Gross Margin %                                   72.6%          64.8%
    Loss from continued operations               (2,759,627)    (2,091,170)
    Loss from discontinued operations              (7,109)        (4,851)
    Loss for the period                          (2,766,736)    (2,096,021)
    Weighted Average no. of shares outstanding
     - basic                                     24,096,044     15,057,098
    Loss per Common Share-basic and diluted        ($0.11)        ($0.14)

    About MedX Health Corp.

    MedX is a leading North American developer and manufacturer of low level
laser and light medical devices for the drug free and non-invasive treatment
of tissue damage and pain in numerous medical settings including dental,
rehabilitation and wound care. MedX is the world's only company focusing on
developing and delivering a broad cross-section of technologies and products
involved in healing using light therapy. MedX is committed to advocating for
and bringing the non-invasive, drug-free healing nature of light to people
seeking relief from pain and other physical ailments. MedX's strategy is to
build upon its success in bringing relief of symptoms in a non-pharmacologic
manner in the rehabilitation market through key partnerships, acquisitions,
strong patent protection as well as developing and commercializing advanced
products in the dental and wound-care markets that will position the company
to increase revenue. In addition, MedX plans to accelerate the development of
a new product aimed at the rapidly-growing wound care market: its
"Photobandage(TM)", a bandage technology that allows a wound to be bathed in
light, designed to enhance the healing process. The Company intends to license
this new technology to one or more major wound care companies for further
development of marketing and sales.
    Brand products are US FDA approved, Health Canada cleared, and CE Marked
and are produced in an ISO 9001 and 13485 certified manufacturing and testing
facility. For a complete profile of MedX Health Corp. and its products visit

    The TSX Venture Exchange does not accept responsibility for the adequacy
    or accuracy of this press release.

    This press release contains "forward-looking information" within the
meaning of applicable Canadian securities legislation. Such forward-looking
information may include statements regarding the Company's future plans,
objectives, performance, growth, profits, operating expenses or its underlying
assumptions. Generally, forward-looking information can be identified by the
use of forward-looking terminology such as "plans", "expects", or "does not
expect", "is expected", "budget", "scheduled", "estimates", "forecasts",
"intends", "anticipates", or "does not anticipate", or "believes" or
variations of such words and phrases or state that certain actions, events or
results "may", "could", "would", "might", or "will be taken", "occur", or "be
achieved". Forward-looking information is subject to known and unknown risks,
uncertainties and other factors that may cause the actual results, level of
activity, performance or achievements of MedX to be materially different from
those expressed or implied by such forward-looking information, including
uncertainty of successful development of new products, uncertainty of
successful manufacturing or marketing of products, uncertainty of commercial
acceptance of products, uncertainty concerning governmental regulation,
dependency on key employees and relationships, rapid technological changes,
foreign currency fluctuations. MedX does not undertake to update any
forward-looking information, except in accordance with applicable securities

    %SEDAR: 00017466E

For further information:

For further information: Investors: Steve Guillen, President and Chief
Executive Officer, MedX Health Corp., Phone: (905) 826-0766,; Media: Terri Clevenger, Continuum Health Communications,
Phone (203) 227-0209, Email:

Organization Profile

MedX Health Corp.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890